Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX), including a biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland. The transaction, valued at US $122.5 million, was executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.
With this acquisition, Bora Group's biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, along with a development facility in Zhubei, Taiwan. This expansion establishes a US biologics manufacturing platform that sponsors can depend on from development through licensed commercial supply.
"As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure," said Bobby Sheng, Chairman and CEO of Bora Group. "Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
The addition of the Rockville facility brings Bora Biologics' support to more than 4 active commercial programs, with over 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada, and the UK. The company maintains fully integrated QC and analytical capabilities across its network.
Bora Biologics' US network has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure.
Bora Group intends to integrate its US drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. This integration is expected to provide clients with a streamlined path from early development to commercial manufacturing, reducing complexity and accelerating time to market.
The implications of this acquisition are significant for the biopharmaceutical industry. As regulatory pressures and supply chain uncertainties persist, particularly in the post-pandemic era, the demand for reliable US-based manufacturing capacity has intensified. Bora's expanded footprint offers a domestic alternative for companies seeking to reduce offshore dependency, potentially reshaping supply chain strategies. For investors and industry leaders, this move signals Bora's commitment to becoming a major player in the biologics CDMO space, competing with established players by offering end-to-end services and a proven regulatory track record.
For more information about Bora Pharmaceuticals and its services, visit https://www.boracdmo.com.
